Can I Take Creatine With Belsomra (Suvorexant)?

What Is Belsomra and How Does It Work?

Belsomra (suvorexant) is the first FDA-approved dual orexin receptor antagonist (DORA) for insomnia disorder, approved in August 2014 at doses of 5, 10, 15, and 20 mg taken no more than 30 minutes before bed [1]. Rather than broadly suppressing central nervous system activity the way benzodiazepines do, suvorexant selectively blocks orexin-1 and orexin-2 receptors to reduce the wake-promoting signal [2].

Mechanism of Action

Orexin peptides (also called hypocretins) are produced in the lateral hypothalamus and bind OX1R and OX2R to sustain wakefulness [2]. Suvorexant competitively antagonizes both receptor subtypes, effectively switching off the arousal signal rather than sedating the entire brain. This selectivity is why next-morning impairment is generally lower with suvorexant than with non-benzodiazepine hypnotics at equivalent efficacy doses [3].

Pharmacokinetics and CYP3A4 Dependence

Suvorexant is almost entirely metabolized by CYP3A4 in the liver, with a median half-life of approximately 12 hours [1]. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) roughly double suvorexant exposure, and the FDA label restricts use with strong inhibitors to a maximum of 5 mg [1]. Strong CYP3A4 inducers (rifampin, carbamazepine) reduce exposure substantially and are listed as drugs to avoid together [1]. Renal excretion accounts for only about 23% of the dose, predominantly as metabolites rather than unchanged drug [1].

What Does Creatine Do in the Body?

Creatine is a nitrogenous compound synthesized endogenously from arginine, glycine, and methionine, primarily in the liver and kidneys [4]. Supplemental creatine monohydrate increases phosphocreatine stores in skeletal muscle, accelerating ATP resynthesis during high-intensity exercise [4]. The International Society of Sports Nutrition (ISSN) position stand states: "Creatine monohydrate is the most effective ergogenic nutritional supplement currently available to athletes" [5].

Standard Dosing and Loading Protocols

A loading phase of 20 g/day (divided into four 5 g doses) for 5 to 7 days can saturate muscle creatine stores rapidly [5]. A maintenance dose of 3 to 5 g/day sustains those stores without loading [5]. Not everyone loads; many recreational athletes begin at 3 to 5 g/day and reach near-maximal saturation within 3 to 4 weeks [5].

Why Creatine Raises Serum Creatinine

Creatine is non-enzymatically converted to creatinine in muscle tissue and excreted by the kidneys [4]. Oral creatine supplementation raises serum creatinine by roughly 10 to 20% above baseline and can raise 24-hour urinary creatinine excretion comparably [6]. A 2003 study in the Journal of the American Society of Nephrology (N=12 healthy adults, 5 g/day for 28 days) reported mean serum creatinine increases of 0.22 mg/dL above baseline, well within the reference range but potentially misread as early renal impairment [6]. Cystatin C, which creatine does not affect, remains a more accurate kidney-function marker in people who supplement [7].

Is There a Direct Pharmacokinetic Interaction Between Creatine and Suvorexant?

No. Creatine does not inhibit, induce, or compete with CYP3A4, CYP2C9, or P-glycoprotein, which are the three main pathways governing suvorexant disposition [1][4]. No published pharmacokinetic study has tested the combination directly, but the mechanistic basis for an interaction is absent.

Absorption and Protein Binding

Suvorexant is approximately 99% protein-bound (primarily albumin) [1]. Creatine is not meaningfully protein-bound and does not displace highly protein-bound drugs at physiologically relevant concentrations [4]. There is no competitive binding concern.

CNS Pharmacodynamic Overlap

Creatine does not produce sedation, CNS depression, or orexin pathway modulation. No additive or synergistic CNS depression is expected [2][4]. Some research suggests creatine may support cognitive performance and mood during sleep deprivation, but this effect operates via cellular energy pathways rather than neuroreceptor modulation [8].

The Real Concern: Creatinine Elevation and Renal Monitoring

This is where clinical vigilance matters. Suvorexant is renally cleared to a modest degree, and the FDA label advises caution in patients with significant renal impairment [1]. If creatine supplementation artificially elevates serum creatinine, a prescribing clinician may overestimate kidney disease severity, alter the suvorexant dose unnecessarily, or flag a false deterioration in renal function [6][7].

How Much Does Creatine Shift Creatinine?

A meta-analysis of 14 randomized trials (N=470 participants) published in the European Journal of Applied Physiology found that short-term creatine supplementation raised serum creatinine by a mean of 0.23 mg/dL (95% CI: 0.16 to 0.31 mg/dL) across loading and maintenance protocols [9]. That shift is clinically small in a healthy adult with a baseline creatinine of 0.8 to 1.0 mg/dL, but it can push a borderline reading past the 1.2 mg/dL threshold used to flag renal impairment in many electronic health records.

Cystatin C as a Superior Biomarker

Cystatin C is filtered by the glomerulus at a constant rate and is not influenced by muscle mass or dietary creatine intake [7]. The 2012 CKD-EPI Creatinine-Cystatin C equation (endorsed by KDIGO 2022 guidelines) provides a more accurate eGFR estimate in people with high muscle mass or creatine supplementation [7]. If your provider needs a reliable eGFR while you are taking creatine, request a cystatin C-based calculation.

Does Suvorexant Itself Harm the Kidneys?

No nephrotoxicity signal has emerged in the suvorexant clinical trial program. The key Phase 3 trials (Study 1, N=1,021; Study 2, N=1,784) did not report renal adverse events as a notable finding at 20 mg and 40 mg doses studied over 3 months [3]. The 40 mg dose is not marketed (the ceiling is 20 mg), and the approved doses have not shown kidney-damaging effects in post-marketing surveillance either [1].

Who Should Be Most Cautious?

Most adults taking suvorexant for insomnia are generally healthy and can add creatine without meaningful risk. Certain groups deserve more careful review before combining the two.

Patients With Chronic Kidney Disease (CKD)

People with CKD stage 3 or higher (eGFR <60 mL/min/1.73 m²) already have restricted reserve. Creatine loading in this population is not well-studied, and the 2017 KDIGO commentary on dietary protein and renal disease advises caution with high nitrogen-containing supplements in progressive CKD [10]. If you have CKD stage 3+, discuss creatine supplementation explicitly with your nephrologist before starting.

Older Adults on Multiple Medications

Adults over 65 already experience a natural decline in eGFR of roughly 1 mL/min/1.73 m² per year [10]. Suvorexant is commonly prescribed in this age group. An artifactual creatinine rise from creatine could mislead a geriatrician into reducing medications that depend on renal clearance calculations.

Athletes in Competition or High-Volume Training

Athletes using creatine at loading doses (20 g/day) and also managing insomnia with suvorexant may experience more pronounced creatinine elevation during the 5-to-7-day loading window. Baseline labs before loading, and a repeat cystatin C-based eGFR at 2 weeks, provide a clean picture.

Practical Dosing and Timing Guidance

No pharmacokinetic data require a specific dose-separation window between creatine and suvorexant. The following framework is based on first principles and standard clinical practice for supplement-drug co-administration.

Recommended Timing Protocol

Take suvorexant 30 minutes before bed as directed on the FDA label [1]. Take creatine monohydrate in the morning or around a workout, which is the standard evidence-based timing for performance benefit [5]. This naturally creates a 10-to-14-hour separation. Even if you prefer evening creatine, separating it by at least 2 hours from suvorexant avoids any theoretical interaction during the absorptive phase, though no interaction has been demonstrated.

Dose Selection

Use the lowest effective suvorexant dose. The FDA label recommends starting at 10 mg; many patients find 10 mg sufficient, reducing exposure and theoretical concerns at higher doses [1]. For creatine, a maintenance dose of 3 to 5 g/day avoids the more pronounced creatinine spike seen during the 20 g/day loading phase [5].

Lab Monitoring Checklist

Before combining creatine with suvorexant, consider the following baseline and follow-up labs:

• Serum creatinine and BUN at baseline
• Cystatin C-based eGFR if baseline creatinine is above 1.1 mg/dL
• Repeat serum creatinine at 4 weeks after starting creatine
• Annual renal panel if ongoing use continues past 6 months

The Endocrine Society does not publish specific guidance on creatine-hypnotic co-administration, but standard supplement safety monitoring applies here as it would for any nitrogen-containing compound in a patient on prescription sleep medications.

What the FDA Label Says About Belsomra Drug Interactions

The FDA-approved prescribing information for suvorexant lists the following interaction categories [1]:

• Strong CYP3A4 inhibitors: Use of suvorexant is not recommended; if necessary, limit to 5 mg.
• Moderate CYP3A4 inhibitors (fluconazole, diltiazem): Limit suvorexant to 10 mg.
• Strong CYP3A4 inducers: Avoid combination; clinical efficacy is substantially reduced.
• CNS depressants (alcohol, opioids, benzodiazepines): Additive CNS depression; use with caution.
• Digoxin: Suvorexant inhibits P-glycoprotein and may increase digoxin exposure; monitor digoxin levels.

Creatine does not appear in any interaction category in the label. It is not a CYP3A4 modulator, a CNS depressant, or a P-glycoprotein substrate [1][4].

Evidence on Creatine Safety: Long-Term Data

Concerns about creatine causing kidney damage have been studied extensively and have not been confirmed in healthy adults. A 2017 systematic review in the Journal of the International Society of Sports Nutrition (covering 22 trials, total supplementation periods of 10 days to 5 years) found no adverse renal effects in people without pre-existing kidney disease [11]. The ISSN position stand states: "There is no compelling scientific evidence that the short or long-term use of creatine monohydrate has any detrimental effects on otherwise healthy individuals" [5]. Three anecdotal case reports of creatine-associated renal impairment from the early 2000s have been criticized for confounding factors including pre-existing disease and concomitant NSAID use [11].

Comparing Interaction Risk: Creatine vs. Common Belsomra Interactions

To put the creatine question in context, the table below shows how it compares to documented suvorexant interactions.

| Co-administration | Interaction Type | Clinical Severity | |---|---|---| | Ketoconazole (strong CYP3A4 inhibitor) | Pharmacokinetic | Contraindicated / dose-restrict to 5 mg | | Diltiazem (moderate CYP3A4 inhibitor) | Pharmacokinetic | Dose-restrict to 10 mg | | Alcohol | Pharmacodynamic (CNS) | Clinically significant; avoid | | Opioids | Pharmacodynamic (CNS) | Clinically significant; caution | | Creatine monohydrate | Indirect (lab artifact) | Minimal; monitor creatinine |

This comparison shows creatine sits at the bottom of the interaction severity spectrum for suvorexant. The concern is not drug toxicity; it is diagnostic accuracy.

Talking to Your Prescriber

Tell your prescriber about creatine supplementation before or at the time Belsomra is prescribed. This is a short conversation. Disclose the dose (typically 3 to 5 g/day maintenance), the frequency (daily), and the duration (ongoing for performance goals). Your provider may order a baseline cystatin C-based eGFR to have a creatine-independent kidney function reference point.

If your serum creatinine rises after starting creatine, ask specifically whether the rise is consistent with creatine supplementation before any medication changes are made. A repeat cystatin C, which should remain stable, can confirm whether the elevation is artifactual [7].

A 2022 KDIGO guideline update reinforced that serum creatinine alone is insufficient for staging CKD when dietary or supplemental creatine intake is elevated, and advised confirmatory testing with cystatin C in such cases [10].